SoftBank Robotics Group Makes Strategic Equity Investment in Avalon SteriTech

SoftBank Robotics Group Corp. (“SBRG”) today announced its strategic equity investment in Avalon SteriTech (“Avalon”), marks a great step forward in strengthening the companies’ collaboration since its joint venture was established in March 2021.

SoftBank Robotics Group notes upon the completion of the transaction, SBRG will own approximately 5% stake in Avalon’s disinfection business. Mr. Kenichi Yoshida, Chief Business Officer of SoftBank Robotics Corp, will take part in its board of directors to support the continuous growth of the company.

The transaction is subject to customary closing conditions and is expected to close by the end of April 2022.

Avalon and SBRG continue to see a strong market demand for robotic disinfection technologies and how they successfully raised the bar of cleaning and disinfection in combatting the ongoing COVID-19 pandemic. In doing so, the two companies strive to innovate smart-cleaning products and customized solutions in Hong Kong and beyond, leveraging Avalon’s strengths in biotechnology and healthcare, and SBRG’s expertise in AI, automation, and robotics.

Building on the success of Whiz Gambit, the 2-in-1 AI-powered cleaning and disinfection robotics solution launched under the joint venture, has successfully extended its footprints worldwide from Asia Pacific to EMEA, forging ahead toward Australia, the United Arab Emirates, and the United States. As the pandemic rages on, Whiz Gambit has been widely adopted by the public sector, hospitality, commercial, and healthcare industries, with over 100 of them serving the city’s extensive railway network in Hong Kong. Hence, Whiz Gambit was also a proud recipient of several international recognitions including the Innovation Honoree (Robotics) at the CES 2022 Innovation Awards.

“We are excited to deepen our strategic partnership with SoftBank Robotics Group, the worldwide leader in robotics solutions. Since last year, we have been working closely in accelerating the adoption of smart disinfection solutions and uplifting the public health standard that transcends conventional concepts of hygiene. The investment from SoftBank Robotics will bring tremendous momentum to our global market expansion, as we continue to work hand in hand with businesses, governments, and societies to safeguard the health and well-being of millions of people around the globe,” said Mr. Lewis Ho, Chief Executive Officer of Avalon SteriTech.

“SoftBank Robotics continues to identify innovative business approaches that enable us to stay at the forefront of providing robotics solutions. Equity investment is a capital efficient way for us to strengthen our participation in the ever-changing competitive robotics landscape. This opportunity to increase our stake and involvement will bolster our disinfection robots category. We are pleased to have found a like-minded partner like Avalon SteriTech, with their extensive knowledge in the biomedical sector, it will be integral to the success of this joint venture”, said Mr. Kenichi Yoshida, Chief Business Officer of SoftBank Robotics Group Corp.

Moving forward, the strategic partnership will focus on creative product development and strengthen business collaboration, from technologies and robotics innovation, business operations, and sales network establishment, setting foot in the dynamic global disinfection market. As the world sees the aviation industry’s recovery making its way, Avalon will be launching a new disinfection robot for mass transportation later this year. Currently, Avalon’s disinfection robot for the sector is serving Cathay Pacific Airways and MTR’s Airport Express for daily disinfection.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”